Welcome to our dedicated page for Alpha Cognition SEC filings (Ticker: ACOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Cognition Inc. (NASDAQ: ACOG) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures. Alpha Cognition is an emerging growth, commercial-stage biopharmaceutical company focused on Alzheimer’s disease and other neurodegenerative conditions, and its filings offer detailed insight into how it finances, governs, and reports on its ZUNVEYL and ALPHA-1062 programs.
Through this page, users can review Current Reports on Form 8-K that document material events such as public offerings of common shares and pre-funded warrants, at-the-market offering agreements, changes in the independent registered public accounting firm, and adoption of equity incentive plans. For example, recent 8-Ks describe an underwriting agreement for a public offering intended to support ZUNVEYL commercialization, an ATM agreement with a sales agent for up to a specified aggregate amount of common shares, and the transition from a Canada-based auditor to a U.S.-licensed firm following relocation of principal executive offices to Texas.
Investors can also use this page to monitor corporate governance and compensation matters, including shareholder votes on the number of directors, director elections, ratification of auditors, and approval of stock incentive plans, as reported in meeting-related filings. These documents help clarify how Alpha Cognition structures its board, aligns management incentives, and complies with exchange and securities regulations.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, financial implications, and governance changes, reducing the time needed to interpret lengthy documents. Real-time integration with the SEC’s EDGAR system means new ACOG filings appear promptly, while dedicated sections for material agreements and capital markets activity make it easier to follow offerings, ATM usage, and other financing tools. For users interested in deeper due diligence on Alpha Cognition’s Alzheimer’s-focused business, this page serves as a structured entry point into the company’s official regulatory record.
Alpha Cognition Inc. director Phillip Joseph Mertz reported new equity awards dated January 14, 2026. He received 7,241 common shares at a price of $0, described as restricted stock units that vest one year from the grant date. He was also granted 8,437 common share options with an exercise price of $6.56, which will vest one year from grant and expire on January 14, 2036.
Following these awards, Mertz directly holds 29,703 common shares and 8,437 options. An additional 12,560 common shares are held indirectly by Mertz Holdings, and he disclaims beneficial ownership of those securities except to the extent of his pecuniary interest.
Alpha Cognition Inc. director Robert James Wills reported equity awards received on 01/14/2026. He was granted 7,241 common shares as restricted stock units at a price of $0, increasing his directly held common shares to 22,241. He also received 8,437 common share options with an exercise price of $6.56 per share and a reported value of $0 at grant, leaving him with 8,437 options held directly.
The filing notes that the restricted stock units vest one year from the grant date, and the options will vest one year from the grant date, with the options expiring on 01/14/2036.
Alpha Cognition Inc. director Leonard Powell Mertz reported new equity awards. On 01/14/2026, he acquired 7,241 common shares as restricted stock units at $0, which will vest one year from the grant date. On the same date, he was granted 8,437 common share options with an exercise price of $6.56; these options also vest one year from the grant date and expire on 01/14/2036.
After these awards, he directly beneficially owned 145,736 common shares and 8,437 common share options. He also indirectly beneficially owned 121,503 common shares through The Len Mertz Trust.
Alpha Cognition Inc. director Kenneth Anthony Cawkell reported new equity awards in the form of common shares and stock options. On January 14, 2026, he received 7,241 common shares at a price of $0, described as restricted stock units that vest one year from the grant date. Following this grant, he directly held 107,740 common shares.
On the same date, he was also granted 8,437 common share options with an exercise price of $6.56 per share, which will vest one year from the grant date and expire on January 14, 2036. The filing also notes indirect holdings of 50,000 common shares through Cawbro Holdings Ltd. and 67,977 common shares through CMI Cornerstone Management Corp., and states that he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Alpha Cognition Inc. director Rajeev Kumar Bakshi reported new equity awards. On 01/14/2026 he received 7,241 restricted stock units of common shares at no purchase price, which vest one year from the grant date. He was also granted 8,437 common share options with a conversion or exercise price of $6.56 per share; these options also vest one year from the grant date.
After these awards, he beneficially owns 12,283 common shares directly and 6,801 common shares indirectly through Vincorp Holdings Ltd., plus 8,437 stock options that can be exercised into common shares once vested.
Alpha Cognition Inc. reported that its Compensation Committee granted new equity awards to senior executives under the 2025 Stock and Incentive Plan on January 9, 2026. These long-term incentives are structured as a mix of restricted stock units (RSUs), stock options, and, for the CEO, performance-based share units.
Chief Executive Officer Michael McFadden received 190,549 RSUs vesting in three equal annual installments from January 9, 2027 to January 9, 2029, 177,576 stock options vesting one-third on January 9, 2027 and quarterly thereafter, and 76,220 performance share units that can vest over two years if the share price reaches levels from $12.00 up to $28.00 for specified trading periods. Chief Operating Officer Lauren D’Angelo received 137,195 RSUs and 106,545 stock options with similar time-based vesting, while Interim Chief Financial Officer Henry Du received 20,579 RSUs and 15,982 stock options on the same vesting schedule.
Alpha Cognition Inc. reported that Chief Executive Officer and director Michael E. McFadden received multiple equity awards on January 9, 2026. He was granted 190,549 restricted stock units at a price of
Alpha Cognition Inc. Chief Operating Officer Lauren D'Angelo received equity awards on January 9, 2026. The filing shows she was granted 137,195 common shares in the form of restricted stock units at a price of $0, vesting one-third on January 9, 2027, one-third on January 9, 2028, and one-third on January 9, 2029.
She was also granted options on 106,545 common shares with an exercise price of $6.56 per share, granted at $0 cost. These options vest one-third on January 9, 2027, with the remaining two-thirds vesting in equal quarterly installments thereafter, and expire on January 9, 2036. Following these grants, she directly holds the full amounts reported.
Alpha Cognition Inc. officer Henry Huy Du, VP Finance and Accounting, reported equity awards dated January 9, 2026. He acquired 20,579 common shares at a price of $0, reported as restricted stock units that vest one‑third on January 9, 2027, one‑third on January 9, 2028, and one‑third on January 9, 2029. He also received 15,982 common share options with an exercise price of $6.56 per share, vesting one‑third on January 9, 2027 and the remainder in equal quarterly installments, and expiring on January 9, 2036. After these grants, he beneficially owns 20,579 common shares and 15,982 options, all held directly.
Alpha Cognition Inc. (ACOG) reported an auditor transition following its move of principal executive offices to Texas. On October 10, 2025, Manning Elliott LLP resigned as independent registered public accounting firm due to licensing requirements in Texas.
The company states there were no disagreements with Manning Elliott on accounting, disclosure, or audit scope, and no reportable events under Regulation S‑K Item 304. Manning Elliott’s prior reports for fiscal years ended December 31, 2024 and 2023 contained no adverse or disclaimed opinions and were not qualified.
With Audit Committee approval on October 10, 2025, Alpha Cognition engaged CBIZ CPAs P.C., a U.S.-licensed, independent registered public accounting firm, and expects a seamless transition.
FAQ
What is the current stock price of Alpha Cognition (ACOG)?
What is the market cap of Alpha Cognition (ACOG)?
